argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$941.25−6.27 (-0.66%)
Close on Nov 18, 2026Market cap –P/E 48.1Yield –
argenx free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was $679.03M. The highest annual figure on record is $679.03M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $679.03M | – |
| FY2024 | Dec 31, 2024 | -$84.55M | – |
| FY2023 | Dec 31, 2023 | -$421.14M | – |
| FY2022 | Dec 31, 2022 | -$863.64M | – |
| FY2021 | Dec 31, 2021 | -$610.44M | – |
| FY2020 | Dec 31, 2020 | -$399.53M | -366.6% |
| FY2019 | Dec 31, 2019 | $149.83M | – |
See a number that looks wrong?